We recently compiled a list of the These 10 Firms Were Last Week’s Worst Performers. In this article, we are going to take a ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

Viking Therapeutics (NASDAQ:VKTX – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at ...

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.87, denoting a +0.67% change from the preceding trading day.

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are ...

Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...

On Thursday, Viking Therapeutics (NASDAQ:VKTX) received a favorable initiation of coverage from Jefferies, with a Buy rating and a price target set at $110.00. The... Biotech firm Viking ...

Viking Therapeutics (NASDAQ:VKTX), currently trading at $32.65, remained in focus as H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating with a price target of $102.00. According to ...

1. Cloudera, Inc. (NYSE:CLDR) broke out of a platform on Wednesday that has been forming for 7 or 8 weeks. It popped 74 cents, or 8 1/2%, to 9.39, just 4 cents off the session ...